Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992573 | 1.00 | BTN3A1 (0.57) | BTN3A1LMNAANPEPLAP3TDP1 | |
| SCHEMBL14466574 | 1.00 | BTN3A1 (0.57) | BTN3A1LMNAANPEPLAP3TDP1 | |
| SCHEMBL807682 | 1.00 | BTN3A1 (0.57) | BTN3A1LMNAANPEPLAP3TDP1 | |
| SCHEMBL20117346 | 0.89 | BTN3A1 (0.47) | BTN3A1LMNAANPEPLAP3MEN1 | |
| SCHEMBL1273013 | 0.88 | BTN3A1 (0.45) | BTN3A1LMNATDP1SMN1; SMN2MEN1 | |
| SCHEMBL13469571 | 0.88 | BTN3A1 (0.47) | BTN3A1ANPEPLAP3MEN1KMT2A | |
| SCHEMBL16015978 | 0.87 | BTN3A1 (0.60) | BTN3A1LMNATDP1POLBMEN1 | |
| SCHEMBL800889 | 0.87 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3MEN1KMT2A | |
| SCHEMBL25387275 | 0.87 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3MEN1KMT2A | |
| SCHEMBL23992574 | 0.87 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20190185507-A1 | Sofosbuvir Derivatives for the Treatment of Hepatitis C | SANDOZ AG (CH) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185507-A1 | Sofosbuvir Derivatives for the Treatment of Hepatitis C | HAVCR2, ZC3HAV1, GTF3C4 | BTN3A1 2643/4885LMNA 3860/4885ANPEP 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.